The U.S. FDA’s  formal evaluation process for medical devices looks at safety and efficacy prior to market clearance. Should economic considerations be added as part of the FDA review? Authors of this editorial claim that you can’t gain a complete picture of the comparative performance of a procedure by focusing on health outcomes alone; you also need to examine costs in relation to the outcomes to show cost-effectiveness. (DIAC)